ARVN
Arvinas, Inc.
Biotechnology · Healthcare · United States
7.90
close · 2026-10-29
value
17
cheaper than peers17
quality
37
stronger fundamentals37
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| price to book | 0.92× | 86 |
| EV to EBITDA | 0.35× | 80 |
| price to sales | 6.06× | 69 |
| earnings yield, 3 years ago | -59.2% | 14 |
| earnings yield, latest year | -12.7% | 14 |
| earnings yield, 1 year ago | -30.9% | 14 |
| cash flow yield, latest year | -47.6% | 5 |
| earnings yield, 2 years ago | -73.8% | 5 |
| cash flow yield, 1 year ago | -45.1% | 5 |
| cash flow yield, 2 years ago | -60.6% | 5 |
| cash flow yield, 3 years ago | -48.4% | 5 |
11 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.2% | 86 |
| return on equity | -42.3% | 57 |
| operating margin | -405.1% | 36 |
| revenue growth | -91.7% | 4 |
4 of 4 measures available
Facts
| market cap | $510M |
| free cash flow | -$199.6M |
| employees | 246 |
| first trade | 2018-09-27 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.14 | -2.77 | -6.62 | -5.31 |
| free cash flow | -$275.7M | -$261.1M | -$350.7M | -$280.3M |
| net income | -$80.8M | -$198.9M | -$367.3M | -$282.5M |
| revenue | $262.6M | $263.4M | $78.5M | $131.4M |